Delphi Study Sample Clauses

Delphi Study. Round 1 For Delphi study round 1 (Annex 1), statements were developed and distributed accordingly in four main stages based on the PPT model (Xxxxxxxxxxxx, Xxxxx and Xxxxxx 1998, Xxxxxxxxxxxx 2006) and the Xxxxxxxxxxxx Compassionate Care Model (Xxxxxxxxxxxx 2014). The first stage ‘Cultural Awareness’ included statements related to ‘self-compassion’ (9 statements) and ‘philosophies’ (6 statements). The second stage ‘Cultural Knowledge’, included statements related to ‘Cultural compassion beliefs’ (5 statements), ‘Cultural compassion values’ (6 statements) and ‘Educational principles’ (8 statements). In the third stage ‘Cultural sensitivity’, 9 statements were included. The fourth stage ‘cultural competence’ included 5 statements. Following agreement with partners, the final document of Delphi study round 1 was sent to the experts (2 from each partner country) (Annex 6). They were asked to reflect on their relevance to a model of culturally competent compassionate leadership and rate the statements on their perceived importance as (a) potential components to be included in a model of care delivery characterized by culturally competent compassionate leadership, and (b) on their clarity; and also to state to which value, principle or philosophy specific to the culturally competent compassion the statement applied.
Sample 1
AutoNDA by SimpleDocs
Delphi Study. Round 2 For the remaining statements, a cross-check was performed, with the needs analysis assessment (as for the values-principles that where thought as the most important by the participants). Therefore, additional statements that were associated with ‘tolerance’, ‘professionalism’, ‘communication skills’, and ‘encouraging’, were developed (Annex 3), as they were missing from the document as modified by the Delphi study – round 1. The sections of Delphi study round 2 were modified as follow: The first stage ‘Cultural Awareness’ included statements related to ‘self-compassion’ (5 statements) and ‘philosophies’ (5 statements). The second stage ‘Cultural Knowledge’, included statements related to ‘Cultural compassion beliefs’ (5 statements), ‘Cultural compassion values’ (5 statements) and ‘Educational principles’ (7 statements). In the third stage ‘Cultural sensitivity’, 4 statements were included. The fourth stage ‘cultural competence’ included 5 statements. Following the approval from the partners, the final document of Delphi study round 2 was send to the experts.
Sample 1
Delphi Study. The Journal of The British Blockchain Association, 1(1), 23-31. Xxxxxxxxxx, X. (2020). Research Note. Rules as Code. Law in Context, 37(1), 1- 8. xxxxx://xxx.xxx/10.26826/law-in-context.v37i1.134 Xxxxxxxxxx, D., Xxxxxxxx, X., Xxxxxxxxxxx, X., & Xxxx, X. X. (2019). Analysis of Ontology Competency Questions and their formalizations in SPARQL-OWL. Journal of Web Semantics, 59, 100534. xxxxx://xxx.xxx/10.1016/j.websem.2019.100534 Xxxxx, X.X., & Governatori, G.(2013). A Study on Translating Regulatory Rules from Natural Language to Defeasible Logics. In RuleML (2). APPENDIX A Table 1. Ontology Methodologies Methodology Year Preparatory Step Development Step Evaluation Step Xxxxxxxxx & Xxx Xxxx, Xxxxxxxxx & Uschold 1995 1. Specify scenario 2. define requirements 3. define terminology 4. Specify definitions and constraints 5. Evaluate with CQ Xxxx, Xxxxxxxxx & Uschold 1995/ 1996 Purpose Ontology building: - Capture - Coding - Integrating Evaluation Methontology10 1997 Specification Conceptualization -glossary -taxonomies -relations -concept dictionaries -axioms & rules Formalization Evaluation Ontology Development 10111 2001 1. Domain & scope 2. Reuse 3. Term list 4. Classes 5. Class properties 6. Slot facets 7. Instantiate OTK Methodology12 2002 (1993) Feasibility study Kickoff (ORSD) Kickoff -source analysis -create draft ont. Refinement -KA experts -draft modification -formalization Evaluation DILIGENT 1 build 10 Xxxxxxxxx-Xxxxx, M., Xxxxx-Xxxxx, A., & Juristo, N. (1997). Methontology: from ontological art towards ontological engineering. In Xxxxxxxx, X. & Xxxxxxxxx, M. (Eds.), Ontological Engineering: Papers from the 1997 Spring Symposium AAAI97, volume Technical Report SS-97-06 (pp. 33–40). American Association for Artificial Intelligence. 11 Noy, N. F. & XxXxxxxxxx, X. X. (2001). Ontology development 101: A guide to creating your first ontology. Technical Report SMI-2001-0880. Stanford University School of Medicine. 12 Xxxx, X., Xxxxx, S., & Xxxxxx, R. (2002). Methodology for development and employment of ontology based knowledge management applications. ACM SIGMOD Record, 31 (Special Issue)(4), 18–23. Xxxx, X. & Xxxxxx, X. (2002). On-to-knowledge methodology - final version. Project Deliverable D. 18, EU IST-1999-10132 On-To-Knowledge. Institute AIFB, University of Karlsruhe. Xxxx, X. & Xxxxxx, X. (2003). A methodology for ontology-based knowledge management. In Xxxxxx, X., Xxxxxx, X., & xxx Xxxxxxxx, X. (Eds.),Towards the Semantic Web. Ontology-driven Kno...
Sample 1

Related to Delphi Study

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Trials The Ship shall run the following test and trials:

  • Case Study Upon Surgi-Vision’s prior written consent in each Instance, Cedara may devise a case-study of any Custom Engineering Services Projects, and may use such case-study for marketing of its engineering services to third parties.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Feasibility Study Buyer will, at Buyer's expense and within ____ days from Effective Date ("Feasibility Study Period"), determine whether the Property is suitable, in Buyer's sole and absolute discretion, for ___________________ use. During the Feasibility Study Period, Buyer may conduct a Phase I environmental assessment and any other tests, analyses, surveys and investigations ("Inspections") that Buyer deems necessary to determine to Buyer's satisfaction the Property's engineering, architectural and environmental properties; zoning and zoning restrictions; subdivision statutes; soil and grade; availability of access public roads, water, and other utilities; consistency with local, state and regional growth management plans, availability of permits, government approvals, and licenses; and other inspections that Buyer deems appropriate to determine the Property's suitability for the Buyer's intended use. If the Property must be rezoned, Buyer will obtain the rezoning from the appropriatx xxxernment agencies. Seller will sign all documents Buyer is required to file in connection with development or rezoning approvals. Seller gives Buyer, its agents, contractors and assigns, the right to enter the Property at any time during the Feasibility Study Period for the purpose of conducting inspections; provided, however, that Buyer, its agents, contractors and assigns enter the Property and conduct inspections at their own risk. Buyer will indemnify and hold Seller harmless from xxxxes, damages, costs, claims and expenses of any nature, including attorney's fees, expenses and liability incurred in application for rezoning or related proceedings, and from liability to any person, arising from the conduct of any and all inspections of any work authorized by Buyer. Buyer will not engage in any activity that xxxxx result in a construction lien being filed against the Property without Seller's prior written consent. If this transaction does not close, Buyer will, at Buyer's expense, (1) repair all damages to the Property resulting from the Inspections and return the Property to the condition it was in prior to conduct of the Inspections, and (2) release to Seller all reports and other work generated as a result of the Inspections. Buyer will deliver written notice to Seller prior to the expiration of the Feasibility Study Period of Buyer's determination of whether or not the Properxx xx acceptable. Buyer's failure to comply with this notice requirement will constitute acceptance of the Property as suitable for Buyer's intended use in its "as is" condition. If the Property is unacceptable to Buyer and written notice of this fact is timely delivered to Seller, this Contract will be deemed terminated as of the day after the Feasibility Study period ends and Buyer's deposit(s) will be returned after Escrow Axxxx receives proper authorization form all interested parties.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

Time is Money Join Law Insider Premium to draft better contracts faster.